OKYO Pharma Limited (OKYO)

Market Cap	48.56M
Revenue (ttm)	n/a
Net Income (ttm)	-13.27M
Shares Out	31.95M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,769
Open	1.510
Previous Close	1.550
Day's Range	1.464 - 1.580
52-Week Range	0.920 - 3.070
Beta	-3.03
Analysts	Strong Buy
Price Target	7.00 (+360.53%)
Earnings Date	May 28, 2024

About OKYO

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, th...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 2022
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: OKYO

Analyst Forecast

According to one analyst, the rating for OKYO stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target

$7.0

(360.53% upside)

Analyst Consensus: Strong Buy